RESUMO
The effects of lidoflazine on exercise tolerance have been tested during a double-blind cross-over trial in 14 male post-infarction patients with a median age of 47 years (range 24-85). Each treatment phase lasted three months. Lidoflazine dosage was one 60 mg tablet t.i.d. At rest, significant decreases in diastolic blood pressure (DBP) and heart rate (HR) were noted during lidoflazine treatment. Bicycle ergometric tests revealed a significant increase in maximum work load and a significant decrease in the product HRXsystolic BP at a 100 W work load during lidoflazine. No similar changes were recorded during placebo periods. Five patients were able to resume their professional activities whilst on lidofalzine, against only two on placebo.
Assuntos
Lidoflazina/uso terapêutico , Infarto do Miocárdio/tratamento farmacológico , Piperazinas/uso terapêutico , Adulto , Pressão Sanguínea/efeitos dos fármacos , Ensaios Clínicos como Assunto , Frequência Cardíaca/efeitos dos fármacos , Humanos , Lidoflazina/farmacologia , Masculino , Pessoa de Meia-Idade , Esforço Físico , PlacebosRESUMO
During the years 1968-71 203 patients with proved myocardial infarction were admitted to the trial. Patients were mobilized either on day 10 (102 patients) or on day 20 (100 patients). All patients were kept in hospital for 30 days in order to ensure a detailed comparison of clinical course and laboratory data. In neither group was there a fatal complication and the differences in clinical outcome or laboratory data were statistically not significant. Half of the patients from each group were re-examined after an average of one-and-a-half years, and again no differences were observed. It is concluded that patients with an uncomplicated myocardial infarction may safely be mobilized after 9 days and discharged after three weeks.
